Selected Publications

Academic Article

Year Title Altmetric
2018 Enhanced Recovery After Surgery in Surgical Specialties: Gynecologic OncologySurgical Clinics of North America.  98:1275-1285. 2018
2018 Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomyGynecologic Oncology.  151:282-286. 2018
2018 Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.Gynecologic Oncology.  151:4-5. 2018
2018 The impact of racial, geographic, and socioeconomic risk factors on the development of advanced-stage cervical cancerJournal of Lower Genital Tract Disease.  22:269-273. 2018
2018 Predictors of Unplanned Reoperation for Ovarian Cancer Patients from the National Surgical Quality Improvement Program DatabaseInternational Journal of Gynecological Cancer.  28:1427-1431. 2018
2018 The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from AlabamaPreventive Medicine.  113:124-131. 2018
2018 High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical CytologyJournal of Lower Genital Tract Disease.  22:207-211. 2018
2018 Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 2018
2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466Oncotarget.  9:19459-19459. 2018
2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer 2018
2017 The evolution of and evidence for opportunistic salpingectomyObstetrics and Gynecology.  130:814-824. 2017
2017 The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysisGynecologic Oncology.  146:642-646. 2017
2017 Preventing human papillomavirus–related cancers: we are all in this togetherAmerican Journal of Obstetrics and Gynecology.  216:576.e1-576.e5. 2017
2017 Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewGynecologic Oncology Reports.  20:81-86. 2017
2017 Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?International Journal of Gynecological Cancer.  27:714-719. 2017
2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growthOncotarget.  8:44159-44170. 2017
2016 Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology serviceGynecologic Oncology.  143:105-108. 2016
2016 Ovarian cancer and the immune system — The role of targeted therapiesGynecologic Oncology.  142:349-356. 2016
2016 Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinomaGynecologic Oncology.  142:25-29. 2016
2016 Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974Laboratory Investigation.  96:249-259. 2016
2016 Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?Gynecologic Oncology.  143:617-621. 2016
2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancerOncotarget.  7:86803-86815. 2016
2015 PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysisGynecologic Oncology.  139:59-62. 2015
2015 Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement projectInternational Journal of Gynecological Cancer.  25:798-801. 2015
2015 A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancerGynecologic Oncology.  136:293-299. 2015
2015 Niclosamide analogs for treatment of ovarian cancerInternational Journal of Gynecological Cancer.  25:1377-1385. 2015
2015 Ovarian and cervical cancer patient derived xenografts: The past, present, and futureGynecologic Oncology.  138:486-491. 2015
2014 Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?World Journal of Stem Cells.  6:441-447. 2014
2014 Outcomes of gynecologic oncology patients undergoing gastrografin small bowel follow-through studies. 2014
2014 Validation of a venous thromboembolism risk assessment model in gynecologic oncology.Gynecologic Oncology.  134:160-163. 2014
2014 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. 2014
2014 Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patientsGynecologic Oncology.  132:227-230. 2014
2014 Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancerInternational Journal of Gynecological Cancer.  24:1480-1485. 2014
2014 Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumabJournal of Nuclear Medicine.  55:1636-1642. 2014
2014 Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancerGynecologic Oncology.  134:112-120. 2014
2014 Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96Gynecologic Oncology.  132:203-210. 2014
2014 Outcomes of gynecologic oncology patients undergoing robotic-assisted laparoscopic procedures in a university settingJournal of Robotic Surgery.  8:207-211. 2014
2014 Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer centerGynecologic Oncology.  133:142-146. 2014
2013 The Wnt/β-catenin pathway in ovarian cancer: A reviewGynecologic Oncology.  131:772-779. 2013
2013 Screening behaviors and cultural barriers in women with newly diagnosed cervical cancer.Journal of Lower Genital Tract Disease.  17:425-429. 2013
2013 Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysisGynecologic Oncology.  130:416-420. 2013
2013 Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinomaAnnals of Surgical Oncology.  20:3059-3065. 2013
2013 Perioperative morbidity and mortality in octogenarians with ovarian cancerInternational Journal of Gynecological Cancer.  23:1006-1009. 2013
2013 Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trialsGynecologic Oncology.  129:251-257. 2013
2013 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women 2013
2012 A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancerGynecologic Oncology.  127:420-425. 2012
2012 The utilization of palliative care in gynecologic oncology patients near the end of life.Gynecologic Oncology.  127:175-179. 2012
2012 Management of complex pelvic masses using a multivariate index assay: A decision analysisGynecologic Oncology.  126:364-368. 2012
2012 Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapyGynecologic Oncology.  126:69-72. 2012
2012 The core competencies of James Marion Sims, MD.Annals of Surgery.  256:193-202. 2012
2012 Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusionGynecologic Oncology.  125:646-648. 2012
2012 The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cellsGynecologic Oncology.  125:226-230. 2012
2012 The use of retinoids in ovarian cancer: A review of the literatureInternational Journal of Gynecological Cancer.  22:191-198. 2012
2011 Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignanciesGynecologic Oncology.  123:54-57. 2011
2011 A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinomaGynecologic Oncology.  122:604-607. 2011
2011 Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancerGynecologic Oncology.  122:532-535. 2011
2011 Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter?International Journal of Gynecological Cancer.  21:1131-1134. 2011
2011 The efficacy and toxicity of bevacizumab in combination with gemcitabine in patients with recurrent ovarian cancerClinical Ovarian Cancer.  4:34-37. 2011
2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer modelGynecologic Oncology.  121:193-199. 2011
2010 Robotic surgery in gynecologic oncology fellowship programs in the USA: A survey of fellows and fellowship directorsInternational Journal of Medical Robotics and Computer Assisted Surgery.  6:405-412. 2010
2010 Overcoming TRAIL resistance in ovarian carcinomaGynecologic Oncology.  119:157-163. 2010
2010 Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignanciesInternational Journal of Gynecological Cancer.  20:103A. 2010
2010 The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancerClinical Ovarian Cancer.  3:52-55. 2010
2009 Life-space assessment in urogynecology and gynecological oncology surgery patients: A measure of perioperative mobility and functionJournal of the American Geriatrics Society.  57:2263-2268. 2009
2009 The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.Gynecologic Oncology.  114:424-426. 2009
2009 The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancerGynecologic Oncology.  114:242-245. 2009
2009 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer modelInternational Journal of Gynecological Cancer.  19:814-819. 2009
2009 Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapyInternational Journal of Gynecological Cancer.  19:888-891. 2009
2009 The management of cervical intraepithelial neoplasia during pregnancy: Is colposcopy necessary?Journal of Lower Genital Tract Disease.  13:182-185. 2009
2009 Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancerGynecologic Oncology.  113:384-390. 2009
2009 In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer.Journal of Clinical Oncology.  27:5503. 2009
2009 The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.Gynecologic Oncology.  112:601-604. 2009
2009 The effect of obesity on survival in patients with ovarian cancerGynecologic Oncology.  112:389-393. 2009
2009 The role of comprehensive surgical staging in patients with endometrial cancer.Cancer Control : Journal of the Moffitt Cancer Center.  16:23-29. 2009
2008 Conservative Management of Postoperative Fever in Gynecologic Patients Undergoing Major Abdominal or Vaginal OperationsJournal of The American College of Surgeons.  207:393-397. 2008
2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effectsVaccine.  26:4314-4319. 2008
2008 Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.Journal of Clinical Oncology.  26:14695. 2008
2008 Lynch syndrome in women less than 50 years of age with endometrial cancerObstetrics and Gynecology.  111:1161-1166. 2008
2008 Lipoxygenase pathway receptor expression in ovarian cancer 2008
2008 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer modelGynecologic Oncology.  108:591-597. 2008
2007 Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma [15]Obstetrics and Gynecology.  110:933-934. 2007
2007 Life Space Assessment in Urogynecology and Gynecologic Oncology Surgical Patients: A Functional Status and Health AnalysisJ Am Urogyn2007
2007 Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experienceInternational Journal of Gynecological Cancer.  17:998-1002. 2007
2007 Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.International Journal of Gynecological Cancer.  17:1019-1024. 2007
2007 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancersGynecologic Oncology.  106:614-621. 2007
2007 Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report.Gynecologic Oncology.  106:265-267. 2007
2007 Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experienceInternational Journal of Gynecological Cancer.  17:886-889. 2007
2007 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice modelGynecologic Oncology.  105:291-298. 2007
2007 A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancerGynecologic Oncology.  105:223-227. 2007
2007 Diagnostic loop electrosurgical excisional procedure for discrepancy: Do preoperative factors predict presence of significant cervical intraepithelial neoplasia?Journal of Lower Genital Tract Disease.  11:69-72. 2007
2007 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer [13]Obstetrics and Gynecology.  109:785. 2007
2006 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancerObstetrics and Gynecology.  108:1375-1379. 2006
2006 Cervical intraepithelial neoplasia in adolescent women: Incidence and treatment outcomesObstetrics and Gynecology.  108:1369-1374. 2006
2006 Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case reportGynecologic Oncology.  103:1141-1143. 2006
2006 Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incisionGynecologic Oncology.  103:749-751. 2006
2006 Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based ChemotherapyJournal of The American College of Surgeons.  203:527-532. 2006
2006 Unilateral cervical cancer in a patient with cervix duplexGynecologic Oncology.  103:346-348. 2006
2006 Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experience.International Journal of Gynecological Cancer.  16:1766-1769. 2006
2006 Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancerGynecologic Oncology.  102:338-342. 2006
2006 Recurrent basosquamous cell carcinoma of the vulvaGynecologic Oncology.  102:400-402. 2006
2006 Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysisCancer.  107:536-543. 2006
2006 Use of complementary and alternative medicine and spiritual practices among women with ovarian carcinoma in the southeastern United States.Journal of Clinical Oncology.  24:15048. 2006
2006 Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer modelGynecologic Oncology.  101:46-54. 2006
2006 Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients 2006
2006 Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhage.Obstetrics and Gynecology.  107:493-496. 2006
2006 Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters)Gynecologic Oncology.  100:219-220. 2006
2005 The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data BaseGynecologic Oncology.  99:530-535. 2005
2005 A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic massesGynecologic Oncology.  99:443-446. 2005
2005 Predictors of outcomes for women with cervical carcinomaGynecologic Oncology.  99:432-436. 2005
2005 Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies.Gynecologic Oncology.  98:490-492. 2005
2005 Management strategies for abnormal early pregnancy: A cost-effectiveness analysis 2005
2005 Feasibility of hand-assisted laparoscopic surgery (HALS) in gynecologic oncology patients.Journal of Clinical Oncology.  23:5153. 2005
2005 A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasiaObstetrical and Gynecological Survey.  60:96-97. 2005
2005 A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy?Journal of Lower Genital Tract Disease.  9:2-6. 2005
2005 Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysisGynecologic Oncology.  97:387-394. 2005
2005 Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancyGynecologic Oncology.  97:713-715. 2005
2005 Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomyGynecologic Oncology.  98:309-312. 2005
2004 Early abdominal incision recurrence in a patient with stage i adenocarcinoma of the endometriumObstetrics and Gynecology.  104:1170-1172. 2004
2004 Some remarks on the somatic expression of sperm protein 17 [1] (multiple letters)International Journal of Cancer.  111:972-973. 2004
2004 A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasiaJournal of Lower Genital Tract Disease.  8:280-284. 2004
2004 The impact of aborted radical hysterectomy in patients with cervical carcinomaGynecologic Oncology.  95:204-207. 2004
2004 Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients.Journal of Clinical Oncology.  22:5044. 2004
2004 Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy.Journal of Clinical Oncology.  22:5083. 2004
2004 Expression of sperm protein 17 (Sp17) in ovarian cancerInternational Journal of Cancer.  108:805-811. 2004
2004 Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series 2004
2004 The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomyGynecologic Oncology.  92:215-219. 2004
2003 A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3American Journal of Obstetrics and Gynecology.  188:1186-1188. 2003
2003 Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigationGynecologic Oncology.  89:233-235. 2003
2003 Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroidsCancer Gene Therapy.  10:377-387. 2003
2003 Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapyGynecologic Oncology.  89:295-300. 2003
2003 Complications of indwelling venous access devices in patients with gynecologic malignanciesGynecologic Oncology.  91:591-595. 2003
2003 Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapyGynecologic Oncology.  91:470-475. 2003
2002 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine ruptureObstetrics and Gynecology.  100:1061-1063. 2002
2002 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture.Obstetrics and Gynecology.  100:1061-1063. 2002
2002 Uterine leiomyosarcoma metastatic to the thyroidObstetrics and Gynecology.  100:1122-1124. 2002
2002 Uterine leiomyosarcoma metastatic to the thyroid.Obstetrics and Gynecology.  100:1122-1124. 2002
2002 A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesisGynecologic Oncology.  87:57-63. 2002
2002 Conservative management of Stage I endometrial carcinoma after surgical stagingGynecologic Oncology.  84:194-200. 2002
2001 Endometrial carcinoma.Current Treatment Options in Oncology.  2:129-135. 2001
2001 Predictors of outcome in small cell carcinoma of the cervix - A case seriesGynecologic Oncology.  83:216-220. 2001
2000 A patient presenting with a pelvic mass, elevated CA-125, and feverGynecologic Oncology.  77:471-472. 2000

Research Overview

  • Cost-effectiveness Analyses
    Surgical Outcomes
    Management of Endometrial Cancer
    Targeted Therapies
    Quality Improvement
    Robotic Surgery
    Enhanced Recovery after Surgery
  • Principal Investigator On

    Investigator On

  • Private Grant  awarded by VBL THERAPEUTICS 2020 - 2025
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by GENMAB 2018 - 2023
  • UAB 1753 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer  awarded by University of Chicago 2018 - 2023
  • Private Grant  awarded by AGENUS, INC. 2020 - 2023
  • Private Grant  awarded by Leap Therapeutics, Inc. 2017 - 2022
  • Private Grant  awarded by MATEON THERAPEUTICS, INC. 2016 - 2021
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2021
  • Private Grant  awarded by PLEXXIKON 2016 - 2021
  • Private Grant  awarded by ABBVIE INC 2015 - 2020
  • Improving Surgical Outcomes and Experience with Patient-Centered Technology  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2018 - 2020
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by Genentech 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2018 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by LICOR, INC. 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2018
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY 2016 - 2017
  • Private Grant  awarded by AMGEN, INC. 2012 - 2016
  • Gynecologic Oncology Group Clinical Trials  awarded by GYNECOLOGIC ONCOLOGY GROUP 2012 - 2016
  • Private Grant  awarded by ASTRAZENECA AB 2014 - 2015
  • Private Grant  awarded by Genentech 2011 - 2013
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 1996
  • Bachelor's Degree in Psychology, Princeton University 1991
  • UAB Hospital, Internship 1967
  • UAB Hospital, Residency 2000
  • UAB Hospital, Residency 1972
  • UAB Hospital, Postdoctoral Fellowship 2003
  • Full Name

  • John Straughn